WO2025067126 - PYRIDONE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND APPLICATION
National phase entry:
Publication Number
WO/2025/067126
Publication Date
03.04.2025
International Application No.
PCT/CN2024/120513
International Filing Date
24.09.2024
Title **
[English]
PYRIDONE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND APPLICATION
[French]
COMPOSÉS DE PYRIDONE ET LEUR PROCÉDÉ DE PRÉPARATION, ET APPLICATION
[Chinese]
一种吡啶酮类化合物及其制备方法与应用
Applicants **
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
Inventors
LAI, Yingjie
LI, Zhongle
XIAO, Ying
ZENG, Junnan
QING, Zhineng
QI, Yinliang
WU, Kang
XIONG, Jinfeng
DENG, Shenglu
LIU, Hanbin
TIAN, Zebing
YUE, Xiaoliang
XIANG, Jiehao
LIU, Xiaoping
Priority Data
202311247773.5
25.09.2023
CN
202311282981.9
28.09.2023
CN
202311284021.6
28.09.2023
CN
202311281664.5
28.09.2023
CN
202311409795.7
26.10.2023
CN
202311453050.0
02.11.2023
CN
202311458387.0
02.11.2023
CN
202311454007.6
02.11.2023
CN
202311555266.8
20.11.2023
CN
202311761849.6
19.12.2023
CN
202311762332.9
19.12.2023
CN
202410157983.3
01.02.2024
CN
202410147418.9
01.02.2024
CN
202410298905.5
14.03.2024
CN
202410517598.5
24.04.2024
CN
202410518428.9
26.04.2024
CN
202410682285.5
29.05.2024
CN
202410703062.2
31.05.2024
CN
202410740895.6
07.06.2024
CN
202410783164.X
17.06.2024
CN
202311282445.9
28.09.2023
CN
202410854908.2
27.06.2024
CN
202410895133.3
04.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5500 | |
| EPO | Filing, Examination, Granting | 35125 | |
| Japan | Filing, Examination, Granting | 3201 | |
| South Korea | Filing, Examination, Granting | 5116 | |
| USA | Filing, Examination, Granting | 15490 |
Total:
64,432
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present application belongs to the technical field of chemical drugs, and relates to the compounds shown in general formulae (A), (B), (C), (D), (E), (F), (G), (H) and (J), or racemates thereof, or isomers and pharmaceutically acceptable salts thereof, which act as PCSK9 inhibitors, and a method for using same to treat various specific diseases or conditions.[French]
La présente invention appartient au domaine technique des médicaments chimiques, et concerne les composés représentés dans les formules générales (A), (B), (C), (D), (E), (F), (G), (H) et (J), ou des racémates de ceux-ci, ou des isomères et des sels pharmaceutiquement acceptables de ceux-ci, qui agissent en tant qu'inhibiteurs de PCSK9, et un procédé d'utilisation de ceux-ci pour traiter diverses maladies ou états spécifiques.[Chinese]
本申请属于化学药物技术领域，涉及一种通式（A）、（B）、（C）、（D）、（E）、（F）、（G）、（H）、（J）所示的化合物，或其消旋体、或其异构体及其可药用的盐，作为一种PCSK9抑制剂以及使用其治疗多种特定疾病或病状的方法。